Replies to post #96920 on Biotech Values

[DewDiligence]

I assume Teva will switch patients and then withdraw the old product [regular Copaxone] from the market.

To my knowledge, this wouldn’t prevent docs from writing a script for regular Copaxone and having it filled by the generic. I’m pretty sure there are others cases where a branded product was withdrawn and its generics continued to be sold.